<DOC>
	<DOCNO>NCT01135251</DOCNO>
	<brief_summary>One hundred consenting AIDS patient suffer treatment induce painful neuropathy blindly randomize Active Placebo group ( ratio A/P = 3/2 receive increase oral dos dimiracetam start 400 mg b.i.d . double dose every two week maximum 1600 mg b.i.d . Escalation high dose allow previous dose cause tolerability problem . The high reach dose maintain total 8 week treatment . Patients must self evaluated pain least 4 10 cm visual analog scale ( VAS ) . Primary end point study number Adverse Events ( AEs ) report placebo versus active group . Preliminary evidence efficacy seek compare active placebo group intensity pain study onset study end . The pain evaluate VAS Total Symptoms Score Clinical Global Impression</brief_summary>
	<brief_title>Safety Preliminary Evidence Efficacy Escalating Doses Dimiracetam AIDS Patients With Painful Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<criteria>male female age 1865 year ; females childbearing potential use medically accept method contraception second method birth control , medically prescribe intrauterine device ( IUD ) , double barrier method ( condom combination spermicidal ) prior screen agree continue use whole duration study ; HIVpositive patient treat ARTs ; CD4+ cell count &gt; 200/L screening ; patient affect neuropathic pain cause ARTs ; naïve neuropathic patient nonresponders ( residual pain ≥40 mm VAS ) standard neuropathy treatment . Drugs neuropathic pain ( NP ) must stop screen visit ; pain intensity ≥40 mm VAS screening ; pain intensity ≥40 mm VAS mean value collect last 4 day prior start treatment ( baseline VAS ) ; life expectancy least 6 month ; ability comprehend full nature purpose study , include possible risk side effect ; ability cooperate Investigator designee comply requirement entire study ; sign write informed consent prior inclusion study pregnant lactating female ; patient neuropathic pain due factor ARTs ; clinically significant underlying disease , accord Investigator 's clinical judgement ; history psychosis ( e.g . schizophrenia psychotic depression ) major depression ; current axis I diagnosis include dementia , depression , psychosis , anxiety disorder , mental retardation ; participation evaluation investigational drug within 3 month prior screen ( 6 month neuropathic pain ) . Use investigational drug dimiracetam study permit ; treatment neurostimulating device spinal cord stimulation ( SCS ) , acupuncture , homeopathic remedy pain kind surgical treatment blockade pain 4 week prior screen ; treatment drug neuropathic pain ( NP ) screen visit ; requirement 2 transfusion / month achieve haemoglobin level &gt; 8 g/dL ; history alcohol abuse ( define accord USDA dietary guideline ) drug abuse last 3 month prior screen ; history allergic response neuropathic treatment history anaphylaxis allergic reaction drug general ; abnormality Investigator deem clinically relevant , either medical history , physical examination , ECG diagnostic laboratory test ; subject likely noncompliant uncooperative study accord Investigator designee 's judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Neuropathic pain</keyword>
	<keyword>AIDS</keyword>
	<keyword>Dimiracetam</keyword>
	<keyword>Treatment related painful neuropathy AIDS patient</keyword>
</DOC>